Streetbeat News

Earnings

CVS

CVS Health (NYSE:CVS) is set to release its latest quarterly earnings report on November 1, 2023. Analysts estimate an earnings per share (EPS) of $2.13. The company's past performance shows a pattern of beating EPS estimates but experiencing a drop in share price. The stock is currently trading at $68.01, down 29.27% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:01 pm

QCOM

Qualcomm (NASDAQ:QCOM) is set to release its latest quarterly earnings report on November 1, 2023. Analysts estimate an earnings per share (EPS) of $1.80. The company's past performance shows it beat EPS estimates last quarter by $0.06, but this was followed by an 8.18% drop in share price. Qualcomm's shares were trading at $107.83 as of October 30, with a 52-week return of -4.72%.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:00 pm

STLA

Stellantis CFO has announced that the impact of the strike on the company's 2023 performance will be significant and will not be fully mitigated. However, the company is planning to take actions to address the situation.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:56 pm

CHK

Chesapeake Energy Corporation (NYSE:CHK) is set to release its Q3 financial results on Oct. 31, 2023. Analysts predict a quarterly earnings of 64 cents per share, down from $5.06 per share in the previous year. The company's revenue is expected to be $1.2 billion, compared to $2.01 billion in the year-ago period. Analysts from Benchmark, Wells Fargo, JP Morgan, Stephens & Co., and UBS have recently revised their ratings and price targets for the company.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:55 pm

ABBV

AMGN

Amgen Inc reported Q3 FY23 sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Total revenues increased 4% Y/Y, driven by a 5% increase in product sales. Adjusted EPS increased 6% to $4.96, beating the consensus of $4.66. However, the company's stock fell by 3.78%. Amgen also raised its FY23 adjusted EPS and revenue guidance. Sales of Amjevita, Amgen's new biosimilar version of AbbVie Inc's arthritis drug Humira, rose 30% to $152 million.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 1:55 pm

AVTX

CDIO

GRTX

KTRA

PFE

SPRC

SRPT

US stocks traded lower following the release of economic reports. Pfizer Inc reported a Q3 loss with a 42% slump in sales. SciSparc Ltd, Cardio Diagnostics Holdings, and Avalo Therapeutics saw their shares rise after positive news, while Kintara Therapeutics, Galera Therapeutics, and Sarepta Therapeutics saw their shares drop due to negative developments.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:52 pm

GLBZ

Glen Burnie Bancorp has reported a Q3 2023 earnings of $0.19 per share, up from $0.13 per share year-over-year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:50 pm

GPN

Global Payments Inc (GPN) reported Q3 FY23 results with a 9% Y/Y increase in adjusted net revenue to $2.232 billion, slightly beating the consensus of $2.226 billion. The company also raised its adjusted EPS outlook for FY23 and is progressing with the integration of EVO Payments. GPN shares are trading higher by around 2%.

Portfolio Pulse from Lekha Gupta

October 31, 2023 | 1:46 pm

SIRI

Sirius XM Holdings Inc reported a flat Q3 FY23 revenue of $2.27 billion, slightly missing the consensus of $2.29 billion. Adjusted EPS of $0.09 beat the consensus of $0.08. Subscriber and advertising revenue remained steady. The company reiterated its FY23 revenue outlook of $9.0 billion. SIRI shares traded higher by 4.90% at $4.39.

Portfolio Pulse from Anusuya Lahiri

October 31, 2023 | 1:46 pm

BKNG

EXPE

TCOM

TRIP

Analysts predict a positive outlook for Trip.com Group Limited (NASDAQ:TCOM), a leader in the Chinese travel sector, as the domestic travel market shows stronger-than-expected demand. The company reported Q2 profits of $89 million, beating analyst expectations, and an increase in sales of over 180% from the same year-ago period. Despite a recent increase in short-side bets on Trip.com’s stock, analysts maintain a Buy rating, with an average price target of $50. The company's stock is currently trading around $35.

Portfolio Pulse from Daniel Harrison

October 31, 2023 | 1:41 pm